166 related articles for article (PubMed ID: 12773076)
21. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
Hazra R; Gafni RI; Maldarelli F; Balis FM; Tullio AN; DeCarlo E; Worrell CJ; Steinberg SM; Flaherty J; Yale K; Kearney BP; Zeichner SL
Pediatrics; 2005 Dec; 116(6):e846-54. PubMed ID: 16291735
[TBL] [Abstract][Full Text] [Related]
22. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance.
Palmer S; Margot N; Gilbert H; Shaw N; Buckheit R; Miller M
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1167-73. PubMed ID: 11522186
[TBL] [Abstract][Full Text] [Related]
23. Experience with tenofovir disoproxil fumarate for antiretroviral therapy.
Stephan C
Expert Opin Pharmacother; 2008 May; 9(7):1197-209. PubMed ID: 18422476
[TBL] [Abstract][Full Text] [Related]
24. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.
Deeks SG; Barditch-Crovo P; Lietman PS; Hwang F; Cundy KC; Rooney JF; Hellmann NS; Safrin S; Kahn JO
Antimicrob Agents Chemother; 1998 Sep; 42(9):2380-4. PubMed ID: 9736567
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ;
J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786
[TBL] [Abstract][Full Text] [Related]
26. A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide.
Wassner C; Bradley N; Lee Y
J Int Assoc Provid AIDS Care; 2020; 19():2325958220919231. PubMed ID: 32295453
[TBL] [Abstract][Full Text] [Related]
27. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.
Olin JL; Spooner LM; Klibanov OM
Ann Pharmacother; 2012 Dec; 46(12):1671-7. PubMed ID: 23136357
[TBL] [Abstract][Full Text] [Related]
28. Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate.
Deeks SG; Barditch-Crovo P; Collier A; Smith A; Miller M; McGowan I; Coakley DF
J Acquir Immune Defic Syndr; 2001 Dec; 28(4):336-9. PubMed ID: 11707669
[TBL] [Abstract][Full Text] [Related]
29. Tenacious tenofovir struts its stuff in a virtual ICAAC.
Huff B
GMHC Treat Issues; 2001 Oct; 15(10):9-11. PubMed ID: 11727571
[No Abstract] [Full Text] [Related]
30. Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.
Harrigan PR; Miller MD; McKenna P; Brumme ZL; Larder BA
Antimicrob Agents Chemother; 2002 Apr; 46(4):1067-72. PubMed ID: 11897591
[TBL] [Abstract][Full Text] [Related]
31. Encouraging results for tenofovir.
AIDS Patient Care STDS; 2001 May; 15(5):289. PubMed ID: 11530770
[No Abstract] [Full Text] [Related]
32. K65R, TAMs and tenofovir.
Miller MD
AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738
[TBL] [Abstract][Full Text] [Related]
33. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
[TBL] [Abstract][Full Text] [Related]
34. Nucleotide HIV reverse transcriptase inhibitors: tenofovir and beyond.
Cihlar T
Curr Opin HIV AIDS; 2006 Sep; 1(5):373-9. PubMed ID: 19372836
[TBL] [Abstract][Full Text] [Related]
35. Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients.
Lerbaek A; Kristiansen TB; Katzenstein TL; Mathiesen L; Gerstoft J; Nielsen C; Larsen K; Nielsen JO; Obel N; Laursen AL; Nielsen SD
Scand J Infect Dis; 2004; 36(4):280-6. PubMed ID: 15198185
[TBL] [Abstract][Full Text] [Related]
36. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.
Valantin MA; Bittar R; de Truchis P; Bollens D; Slama L; Giral P; Bonnefont-Rousselot D; Pétour P; Aubron-Olivier C; Costagliola D; Katlama C;
J Antimicrob Chemother; 2010 Mar; 65(3):556-61. PubMed ID: 20053692
[TBL] [Abstract][Full Text] [Related]
37. Can AIDS drug also prevent HIV infection?
AIDS Read; 2004 Jan; 14(1):14. PubMed ID: 14959699
[No Abstract] [Full Text] [Related]
38. Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate.
Guo Y; Fung HB
Pharmacotherapy; 2004 Aug; 24(8):1089-94. PubMed ID: 15338857
[TBL] [Abstract][Full Text] [Related]
39. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.
De Clercq E
Clin Microbiol Rev; 2003 Oct; 16(4):569-96. PubMed ID: 14557287
[TBL] [Abstract][Full Text] [Related]
40. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.
Barditch-Crovo P; Deeks SG; Collier A; Safrin S; Coakley DF; Miller M; Kearney BP; Coleman RL; Lamy PD; Kahn JO; McGowan I; Lietman PS
Antimicrob Agents Chemother; 2001 Oct; 45(10):2733-9. PubMed ID: 11557462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
